Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 2321Neoplasms 1688Prostatic Neoplasms 1187Lung Neoplasms 914Colorectal Neoplasms 875Carcinoma, Non-Small-Cell Lung 849Leukemia, Myeloid, Acute 585Pancreatic Neoplasms 573Multiple Myeloma 545Carcinoma, Hepatocellular 515Brain Neoplasms 513Neoplasm Metastasis 462Head and Neck Neoplasms 459Melanoma 414Ovarian Neoplasms 409Glioblastoma 399Precursor Cell Lymphoblastic Leukemia-Lymphoma 388Stomach Neoplasms 371Uterine Cervical Neoplasms 359Squamous Cell Carcinoma of Head and Neck 356Rectal Neoplasms 335Recurrence 334Hematologic Neoplasms 327Sarcoma 324Lymphoma 314Colonic Neoplasms 314Triple Negative Breast Neoplasms 285Urinary Bladder Neoplasms 283Glioma 278Carcinoma, Renal Cell 278

Interventions

tetracarboxyphenylporphine 1testosterone enanthate 1testosterone 17 beta-cypionate 1olaparib 1Testosterone Propionate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Castration-Resistant Prostate Carcinoma × 1 year × Clear all
NCT03516812 2025-09-29

Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer

University of Washington

Phase 2 Completed
36 enrolled 14 charts
Genitourinary

Castration-Resistant Prostate Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡